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Introduction
Osteoarthritis (OA) is the most common joint disease and a
major cause of disability. According to the National Health
Interview Survey, more than 50 million adults have been
diagnosed with OA in the United States in 2012.1 The knee is
the one of the most commonly affected joint, and X-ray
evidence of knee OA is diagnosed in up to 60% of people older
than 45 years.2
The etiology of OA is multifactorial and still not
completely understood. Age, obesity, lower-limb malalign-
ment, cartilage defects, joint instability, previous fractures,
and meniscectomy surgery are all strongly correlated to
knee OA.3 Recently, literature reports suggested a female
predisposition for developing knee OA.4 Overall, any
condition that can cause articular damages, and all unfavor-
able biomechanical conditions, which result in mechanical
overload that exceeds the ability of a joint to maintain itself,
predisposes the knee to OA.5
During the past fewdecades, increased emphasis has been
placed on the biochemical balance required for the health of
the cartilage. It has become evident that the inﬂammatory
mediators contribute signiﬁcantly to the development and
progression of structural changes in the OA joint.6 Because
the induction of proinﬂammatory mediators in cartilage,
synovial membrane, and subchondral bone and their signal-
ing pathways are interlinked and overlapped, it therefore
remains controversial whether inﬂammatory mediators are
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Abstract Purpose The purpose of this study was to determine the safety efﬁcacy and outcomes
of platelet-rich plasma (PRP) intra-articular injections for early stages of knee osteoar-
thritis (OA).
Methods Twenty-ﬁve patients affected by grade I and II knee primary OA according to
the Kellgren–Lawrence scale received a single intra-articular PRP injection. Patients
were prospectively evaluated for 6 months. Visual analog scale (VAS), Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC), and Knee injury and
Osteoarthritis Outcome Score (KOOS) scoring scales were used to evaluate clinical
outcomes. Wilcoxon signed rank test was used to evaluate signiﬁcance of improve-
ment of WOMAC, KOOS, and VAS scores.
Results Twenty-one patients completed 6-months follow-up. The median WOMAC
score improved from 29.1 points (range: 17.4–60.4; standard deviation [SD] ¼ 13.0)
at baseline to 42.41 (range: 24.3–71.2; SD ¼ 12.5) at ﬁnal follow-up. Improvements in
median KOOS and VAS score have been also found, from 37.49 points and 64.2 mm
before injection to 59.71 points and 42.8 mm, respectively. All these improvements
were statistically signiﬁcant (p < 0.05). No adverse reactions have been observed.
Conclusion Treating knee OA with PRP injection is safe. A single dose of PRP seems to
be effective in managing pain and improving quality of life in patients with low-grade
knee OA.
Level of Evidence Level IV, therapeutic case series.
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primary or secondary regulators of cartilage damage and the
defective repair mechanisms in OA.7 Therefore, compounds
that regulate cytokine and transglutaminases (TGs) synth-
esis and activity are considered as favorable targets for future
OA therapy. Recent research focused on the anti-inﬂamma-
tory effects of platelet-rich plasma (PRP). PRP is not only a
rich source of growth factors but also contains leukocytes,
some residual erythrocytes, metalloproteinases (MMPs),
coagulation factors, and membrane glycoproteins. All these
components seem to be able to inﬂuence inﬂammation by
regulating the synthesis of other integrins, interleukins (ILs),
chemokines, and cytokines.8 However, PRP products can
vary greatly, even in basic aspects such as their platelet
concentration or the content of white blood cells, and this
may inﬂuence the results.
In vitro studies showed that PRP, in particular leukocyte-
rich plasma (L-PRP), is able to suppress inﬂammatory med-
iator concentration and gene expression in synovium and
cartilage tissue,9 and this could explain the pain improvement
and promising results in some clinical series. Although there
have been many clinical studies on the anti-inﬂammatory
effects of corticosteroids and hyaluronic acid (HA) injections
for knee OA,10 clinical studies using PRP are limited.
The aim of this study was to determine the clinical effect
and outcomes of PRP intra-articular injections for early
stages of knee OA. The hypothesis of the study was that
PRP can become an important pain and inﬂammation med-
iator, especially in early stages of knee OA.
Methods
Participants
Twenty-ﬁve patients matching strict inclusion and exclusion
criteria received one single PRP injection each for knee OA at
our institution and were enrolled in this study in 2014. The
procedure was performed after the patients had signed a
written consent and the study was approved by the local
ethics committee.
Inclusion criteria were patients affected by grade I and II
knee primary OA according to the Kellgren–Lawrence scale.
Exclusion criteria were knee OA grade equal to or greater
than III, history of previous knee surgery, posttraumatic knee
OA, and previous inﬁltrative treatment of the affected knee.
We also excluded patients affected by rheumatic diseases,
diabetes mellitus, and hematological disease (coagulation
disorder). Patients with platelet count of less than 150,000/
mL were excluded from the treatment.
Radiographic examination performed prior to treatment
(T0) included standard weight-bearing X-ray of the affected
knee in anteroposterior and laterolateral views and Rosen-
berg view.
Interventions
PRP preparation was performed as follows. A 50-mL venous
blood sample was collected from each patient and centri-
fugedwith GPS II system (Biomet Biologics,Warsaw, Indiana,
United States) for 15 minutes at a speed of 3,200 rpm. The
mean volume obtained in this series was 7.43 mL of PRP for
intra-articular administration. The whole process lasted
approximately 20 minutes.
The patient was placed in a supine position with the knee
in 90-degreeﬂexion. The skinwas disinfectedwith alcohol or
iodine-based antiseptic solution and draped. PRP was in-
jected very slowly in a sterile condition using a 22-gauge
needle through the anterolateral “soft spot.” Immediately
after administration, gentle passive ﬂexion and extension
exercises of the knee were encouraged. After the injection,
the patientsweremonitored for 10minutes before discharge.
The patients were advised to not take any nonsteroidal anti-
inﬂammatory drugs (NSAIDs) or to apply local ice for a week
after injection to avoid reduction efﬁcacy on PRP. In the
patients with bilateral OA, both knees were injected. All
knees received a single intra-articular PRP injection. None of
the patients received physical therapy after the injection.
Outcome Measurements
All patients were clinically examined on follow-up by a
physician who was not involved in PRP inﬁltration proce-
dure. All the patients were evaluated using the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) and Knee injury and Osteoarthritis Outcome Score
(KOOS) scoring scales.11,12 The questionnaires were admi-
nistered at baseline (T0) and 6 months after PRP injection
(T1). Visual analog scale (VAS) score was recorded before
treatment and at ﬁnal follow-up.13 Demographic character-
istics of the patients as well as complications and adverse
events during treatment were recorded.
Data Analysis
Statistical analysis was performed using GraphPad Prism v
6.0 software (GraphPad Software Inc.). Data were expressed
as the mean  standard deviation. D’Agostino–Pearson nor-
mality test was used to test the normality of data distribu-
tion. Data were normally distributed, and paired
comparisons were performed by two-tailed paired t-test.
The signiﬁcance level was set at p-value lower than 0.05.
Results
Fifteen females (60%) and ten males (40%) with mean age of
49.7 years (range: 79–42 years) were enrolled. Preoperative
plain radiographs showed grade I and grade II primary OA in
8 and 17 patients, respectively. Of them, 21were evaluated at
after 6 months (T1), whereas 4 patients were lost at ﬁnal
follow-up (►Fig. 1). MeanWOMAC score at baselinewas 29.1
 13.0, mean KOOS score before injection was 37.5  18.1,
and mean VAS was 64.2  14.6. At 6 months follow-up, the
mean WOMAC score improved to 42.4  12.5, and the mean
KOOS score was 59.7  17.13. Improvements inWOMAC and
KOOS score were statistically signiﬁcant (p ¼ 0.0004 and
p < 0.0001). We also found a signiﬁcant improvement of
the mean VAS score (42.8  10.5; p < 0.0001), with all but
one patient reporting pain relief 6 months after the proce-
dure. We did not observe any adverse reactions or other
possible serious complications such as infection after PRP
injection.
Joints Vol. 5 No. 1/2017
PRP Injections for Early Knee OA Martini et al. 3
Discussion
The main ﬁnding of this study is that PRP injection is an
effective and safe treatment for low-grade knee OA in terms
of improving function and reducing pain at short-term
follow-up. This contributes to achieve the established goals
for the treatment of knee OA, such as relieving pain, improv-
ing function, increasing quality of life, and, ﬁnally, reducing
disability.14,15 A variety of modalities have been used in the
treatment of knee OA, including both conservative methods
and surgical methods. PRP has showed promising results for
the treatment of various musculoskeletal injuries and has
gained popularity in the treatment of knee OA due to its ease
of use, low cost, and minimally invasive nature.16 However,
the exact mechanisms underneath its efﬁcacy still have to be
fully understood, and often its administration is suggested
on empiric rather than scientiﬁcally validated basis.
The etiopathogenesis of OA is complex and involves many
mechanical and biochemical processes. Aging is the most
important single risk factor of OA, and any unfavorable
biomechanical environment results in mechanical demand
that predispose to articular cartilage damage.3 However, OA
is not related to only mechanical stress, but many cellular
and biochemical processes are also involved in its pathogen-
esis.17 In normal conditions, cartilage extracellular matrix is
in a dynamic equilibrium. In particular, the balance between
anabolic and catabolic activities of chondrocytes maintains
the structural and functional integrity of cartilage.18 In OA, a
deregulated balance between proteinases degrading the
extracellular matrix and their inhibitors may be responsible
for cartilage degeneration.19
Histomorphometrical and biomolecular investigations
showed an increase of inﬂammatory mediators and of
TG-2 expression in human and experimental OA.20 TGs have
been implicated in the formation and development of hard
tissue, extracellular matrix maturation, and mineralization
in growth plate cartilage. They are also involved in organo-
genesis, tissue repair, and many pathological process.21
TG-2, also known as tissue TG, is implicated in joint tissue
remodeling, with particular reference to the interplay with
inﬂammatory mediators of OA. The capacity of transamida-
tion by TG-2 to regulate activation of latent transforming
growth factor beta (TGF-β) seems to have a potential impact
on the regulation of inﬂammatory response in osteoarthritic
tissues.14 TG-2 is also able to activate the crystal-promoting
factor TGF- β1, and an overexpression of TGF-β1was found in
laboratory of OA models.22 TGF-β1 seems to play an im-
portant role inmaintaining chondrocytehypertrophy,which
is typically present near sites of cartilage surface damage,
and it has also been recognized as a crucial factor in the
process of osteophyte formation.23 Finally, inﬂammatory
mediators implicated in OA, including IL-1, stimulate chon-
drocyte matrix calciﬁcation.24 Others inﬂammatory media-
tors such as matrix MMP-1, IL-6, IL-8, and chemokine (C-C
motif) ligand 5 are present and signiﬁcantly higher in the
synovial ﬂuid of patients with OA compared with normal
patients.6 These data conﬁrm the complex role of TG-2 and
inﬂammatory mediators during osteoarthritic joint tissue
remodeling and may play an important role in the develop-
ment of OA. However, it is not well known that if they are
starters or just the consequence of degenerative process of
articular cartilage, and certainly, they are not the only
pathogenetic mechanism in the osteoarthritic process.
Recent in vitro studies showed an anti-inﬂammatory
effect of PRP.9 PRP is not only a rich source of growth factors,
but it also contains antibacterial and fungicidal proteins,
MMPs, coagulation factors, and membrane glycoproteins
that inﬂuence inﬂammation by inducing the synthesis of
other integrins, ILs, chemokines, and cytokines.25 El-Shar-
kawy et al26 used monocyte culture to assess cytokine and
chemokine levels, as well as monocyte chemotactic migra-
tion, in the presence and absence of PRP. They showed that
monocyte chemotactic protein-1, which is released by
monocytes in response to proinﬂammatory stimuli, was
signiﬁcantly decreased by PRP in monocyte culture com-
pared with untreated cells, suggesting that PRP can act as an
anti-inﬂammatory agent by producing endogenous anti-
inﬂammatory factors and by affecting monocyte cytokine
release.Mazzocca et al27developed an invitro study to assess
the anti-inﬂammatory effects of PRP on stimulated human
umbilical vein endothelial cells either alone or in combina-
tion with the corticosteroid or NSAIDs. The authors con-
cluded that PRP reduces cellular inﬂammation compared
with control. However, only one study has directly addressed
effects of PRP on chondrocytes. Sundman et al28 assessed the
anti-inﬂammatory effects of PRP in an ex vivo coculture
model for OA using human cartilage and synovium and
Assessed for eligibility (n = 30) 
Excluded (n = 5) 
♦   Not meeting inclusion criteria (n = 5) 
♦   Declined to participate (n = 0) 
♦   Other reasons (n = 0) 
Lost to follow-up (n = 4) 
Enrolled for intervention (n = 25) 
♦ Received intervention (n = 25) 
♦ Did not receive intervention (n = 0) 
Analysed (n = 21) 
♦ Excluded from analysis (n = 0) 
Fig. 1 Flow diagram of the study.
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concluded that PRP can stimulate endogenous HA synthesis
while decreasing cartilage catabolism and that it can also act
to suppress inﬂammatory mediator concentration in syno-
vium and cartilage tissue. A recent review concluded that
although the effectors mediating the beneﬁcial effects of
PRPs have not been identiﬁed, PRP could act as an endogen-
ous source of chondroprotection by interferingwith the early
catabolic and inﬂammatory events and by subsequently
promoting anabolic responses.29
Another important fact to be considered, is that many PRP
formulation are available for clinical uses and products can
vary greatly, and it may inﬂuences the efﬁcacy of treatment
and the results of clinical trials. Ehrenfest et al30 proposed a
classiﬁcation based on platelet, ﬁbrin, and leukocyte concen-
tration: pure PRP (P-PRP), leukocyte- andplatelet-richplasma,
pure platelet-rich ﬁbrin, and leukocyte- and platelet-rich
ﬁbrin. In particular, the content and different concentration
of leukocytes in PRP products may affect the anti-inﬂamma-
tory effects of PRP. We used L-PRP type because it has been
identiﬁed to improve cellular chemotaxis, proliferation and
differentiation, angiogenesis, and production of extracellular
matrix, and also being responsible for stimulating defense
mechanisms against infections. The role of leucocytes in PRP is
a controversial issue in literature, and it has not been proven
that taking leucocytes from a PRP sample could either beneﬁt
or result better outcomes for the patient.
McCarrel et al31 demonstrated using tendonlike cells har-
vested and cultured from horse ﬂexor digitorum superﬁcialis
tendons that an increase in leukocyte content of PRP products
is positively correlated with an increased expression of in-
ﬂammatory cytokines and that platelet/leukocyte ratio had no
inﬂuence on this effect. Among PRP formulations, a further
division can be made between those activated ex vivo with
thrombin and/or calcium and those inactivated, which rely on
in vivo activation through endogenous collagen.32
Several authors have noticed reduction in pain after PRP
application as reported in our study. However, an explanation
of this phenomenon has not always been given. Crane and
Everts believe that serotonin release from activated platelets
might be responsible for decreased pain.33 Except for the
growth factors in the alpha-granules, large amounts of ser-
otonin are contained within the dense platelet granules.34
Clinical studies on the anti-inﬂammatory effects of PRP
injections are limited. A recent systematic review on the use
of PRP in intra-articular knee injections for OA has been
published. Eight studies published between 2010 and 2013
were included, and all of them showed the efﬁcacy of PRP in
improving function and quality of life and in reducing pain.35
When PRP injections were compared with HA, the results of
the studies did not reveal superiority of PRP. Cerza et al36 in
their randomized controlled trial compared 120 patients
treated with PRP (60 patients) and HA (60 patients) at a
ﬁnal follow-up at 24 weeks. Each patient received four intra-
articular injections, and the authors found signiﬁcantly
better clinical outcome in PRP group compared with HA
group, with lowerWOMAC scores. In contrast, other authors
did not ﬁnd any statistically signiﬁcant improvement with
PRP compared with HA.7
The long-term efﬁcacy of PRP and the number of doses to
administer is another debating matter because all studies
published in literature to date have a short-term follow-up
(maximum 2 years), and only one long-term study suggests
that the beneﬁts of PRP are not sustainable.37We also choose
to use a single L-PRP administration because there is evi-
dence of no signiﬁcant differences between a single dose and
multiple doses, and therefore a less invasive treatment could
be performed.37 This should represent an advantage com-
pared with three HA injections or more and also in terms of
cost-efﬁcacy.
Therefore, authors agree that PRP could be an effective
treatment in the short term to improve patients’ function,
quality of life, and reduce pain,38 as it is reﬂected in the
results of this study. According to literature, results areworse
in patients with gonarthrosis greater than grade II.16
Themost relevant and clinically signiﬁcantﬁndings of this
study were a notable improvement in symptoms related to
knee OA process, especially pain, demonstrated in the results
of the VAS scale in this study, and an improvement in quality
of life, with a high rate of satisfaction as evidenced by the
results of KOOS and WOMAC questionnaires. Moreover, we
proved that a single dose of L-PRP can achieve satisfactory
results, reducing procedure-related morbidity and costs in
comparison to multiple doses schemes that have been used
traditionally in previous studies.
The advantage of this treatment is that even if themechan-
isms leading to clinical effects are still to be understood,
current literature agrees on safety of PRP, with no serious
complications reported.37 Minor adverse events associated
with repeated intra-articular injections include moderate
pain, swelling, and mild effusion that lasted a few days,3 as
shown in this study,whereno adverse effectswere reported.39
We acknowledge the limitations of this study. One limita-
tion of this study is a relatively short follow-up that cannot
assess long-term results of intra-articular knee PRP, which
would determine whether there is some inﬂuence on the
progression of the ostheoarthritic disease or just a relieving
of symptoms. The small sample size is also another limitation
of the study. The absence of a control group does not allow to
draw a clear superiority of PRP injection compared with the
other available treatments. Thus, knee OA is a chronic dis-
ease, and long-term outcomes should be an important con-
sideration in evaluating new treatments. Therefore, our
short-term follow-up (6 months) does not allow us to state
if these results are maintained along time and to draw
deﬁnitive conclusions.
In conclusion, a single dose of PRP in patients with knee OA
grade I or II is a safe an effective treatment for managing the
symptoms associatedwith this pathology, especially pain, and
achieving improvements in quality of life of patients.
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